Private: Fullwidth Portfolio Post


CADTH will be implementing an application fee for manufacturer applications filed with the pan-Canadian Oncology Drug Review (pCODR). The proposed fee will apply to all manufacturer applications with a Health Canada Notice of Compliance (NOC) or Notice of Compliance with Conditions (NOC/c) date of April 1, 2015 or later. The ... Read More


Pilot Extension for Individual Patient Input to the Common Drug Review The Common Drug Review (CDR) is extending its pilot to receive patient input submissions from individual patients and caregivers until August 3, 2015. Pilot Extension for Patient Input for Therapeutic Reviews CADTH implemented a pilot process for receiving patient input submissions for ... Read More


Common Drug Review The Canadian Agency for Drugs and Technologies in Health posted the Canadian Drug Expert Committee (CDEC) final recommendation for its first review of a subsequent entry biologic on its website yesterday. Below is an excerpt from the CDEC Final Recommendation. Recommendation: ... Read More


Common Drug Review patient input submission system CADTH has added new safeguards allowing them to better track submissions automatically: Online & email confirmations for successful uploads Submissions can now be uploaded until midnight on the date of the specified deadline, in all Canadian time zones   2015 CADTH Symposium CADTH is offering funding to help patient ... Read More


The Canadian Agency for Drugs and Technologies in Health (CADTH) revised its Guidelines for Manufacturers on Application Fees for the Common Drug Review. A draft version was circulated for stakeholder feedback in July, following which the below key changes were made: Fees for resubmission based on new clinical information ... Read More


Direct-Acting Antivirals for Chronic Hepatitis C Genotype 1: Draft recommendations posted, feedback requested Yesterday the Canadian Agency for Drugs and Technologies in Health (CADTH)posted on its website the draft Canadian Drug Expert Committee (CDEC) recommendations report stemming from itsrecent therapeutic review project to assess the clinical and economic impact ... Read More


The Canadian Agency for Drugs and Technologies in Health (CADTH) is requesting stakeholder feedback on its draft guidance document, released today, concerning its recent announcement to introduce industry application fees for manufacturer submissions and resubmissions made to the Common Drug Review. The draft Guidelines for Manufacturers on Application Fees ... Read More


An updated table with the targeted Canadian Drug Expert Committee (CDEC) meeting dates is now available on the CADTH website A CDEC meeting will be held in December 2014 as part of an initiative to eliminate an accumulation of CDR submissions. CADTH is extending the pilot process for receiving patient input ... Read More


Effective July 2, 2014, patient groups will now have 35 business days to prepare and submit their patient input submissions to CDR This is possible due to the mandatory pre-submission advance notice policy which will be going into effect the same day. As per the policy, manufacturers must provide a minimum ... Read More


CDR Consultation – Patient Input Template for Subsequent Entry Biologics (SEB) CADTH has developed a patient input template for SEBs and is now seeking feedback on the proposed template. Feedback should be emailed by June 6, 2014 to Temporary Suspension of a CDR Review Due to Incomplete Information CADTH has recently encountered CDR submissions with ... Read More